

COVID-19 Guidance

March 18th, 2021



Supporting Links

<https://www.cms.gov/covidvax-provider>

<https://www.cms.gov/outreach-and-education/outreachffsprovpartprogprovider-partnership-email-archive/2020-10-28-mlnc-se>

<https://www.cms.gov/files/document/COVID-19-toolkit-issuers-MA-plans.pdf>

https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19Vaccination-Program-Interim_Playbook.pdf

<https://www.hrsa.gov/CovidUninsuredClaim>

[COVID-19 Vaccines and Monoclonal Antibodies | CMS](#)

[2021-03-04-MLNC | CMS](#)

[Resources & Links for Kidney Patients \(esrdnetworks.org\)](#)

- [ESRD NCC \(Upcoming Webinar Registrations\)](#)



Provider Agreements

To receive free supplies of the COVID-19 vaccine(s), pharmacies, retail clinics, providers, and any other site of care receiving and administering COVID-19 vaccines must sign an agreement with the U.S. government.

All providers:

1. Must vaccinate individuals regardless of whether they have health insurance coverage or what type of coverage they have.
2. Are prohibited from balance billing or otherwise charging vaccine recipients.
3. Vaccine recipients must be provided with EUA Fact Sheets on the vaccine and vaccination cards.
4. They must also meet storage and recordkeeping requirements, including recording the administration of the vaccine to patients in their own systems within 24 hours, and reporting to public health data systems as soon as practical, and within 72 hours. For more information on the CDC recordkeeping requirements, see the link below:

https://www.cdc.gov/vaccines/imz-managers/downloads/COVID-19Vaccination-Program-Interim_Playbook.pdf



Coverage

As a condition of receiving free COVID-19 vaccines from the federal government, providers will be prohibited from charging consumers for administration of the vaccine. To ensure broad and consistent coverage across programs and payers, the toolkits have specific information for several programs, including:

Medicare: Beneficiaries with Medicare pay nothing for COVID-19 vaccines and their copayment/coinsurance and deductible are waived.

Medicare Advantage (MA): For calendar years 2020 and 2021, Medicare will pay directly for the COVID-19 vaccine and its administration for beneficiaries enrolled in MA plans. MA plans would not be responsible for reimbursing providers to administer the vaccine during this time. Medicare Advantage beneficiaries also pay nothing for COVID-19 vaccines and their copayment/coinsurance and deductible are waived.



Coverage

Medicaid: State Medicaid and CHIP agencies must provide vaccine administration with no cost sharing for most beneficiaries during the public health emergency. Following the public health emergency, depending on the population, states may have to evaluate cost sharing policies and may have to submit state plan amendments if updates are needed.

Medi-Cal Updates:

Pfizer-BioNTech: COVID-19 Vaccine Guidelines: http://files.medi-cal.ca.gov/pubsdoco/Pfizer_BioNTech_COVID19_Vaccine.aspx


Moderna: COVID-19 Vaccine Guideline: http://files.medi-cal.ca.gov/pubsdoco/Moderna_COVID19_Vaccine.aspx

Janssen: COVID-19 Vaccine Guidelines: https://files.medi-cal.ca.gov/pubsdoco/Janssen_COVID19_Vaccine.aspx

Article: COVID-19 Vaccine Administration: Medical and Outpatient Claims Can Be Submitted:

https://files.medi-cal.ca.gov/pubsdoco/newsroom/newsroom_30717_24.aspx

Private Plans: CMS, along with the Departments of Labor and the Treasury, is requiring that most private health plans and issuers cover a recommended COVID-19 vaccine and its administration, both in-network and out-of-network, with no cost sharing. The rule also provides that out-of-network rates cannot be unreasonably low, and references CMS's reimbursement rates as a potential guideline for insurance companies.



Coverage

Uninsured: For individuals who are uninsured, providers will be able to be reimbursed for administering the COVID-19 vaccine to individuals without insurance through the Provider Relief Fund, administered by the Health Resources and Services Administration (HRSA).

Providers administering the vaccine to people without health insurance or whose insurance does not provide coverage of the vaccine administration can request reimbursement for the administration of the COVID19 vaccine through the Provider Relief Fund:

<https://www.hrsa.gov/CovidUninsuredClaim>

[HRSA COVID-19 - Overview \(linkhealth.com\)](#)



Payment Rate

The Medicare payment rates will be \$28.39 to administer single-dose vaccines.

For a COVID-19 vaccine requiring a series of two or more doses, the initial dose(s) administration payment rate will be \$16.94, and \$28.39 for the administration of the final dose in the series.

These rates will be geographically adjusted and recognize the costs involved in administering the vaccine, including the additional resources involved with required public health reporting, conducting important outreach and patient education, and spending additional time with patients answering any questions they may have about the vaccine.

Special Edition - Monday March 15, 2021:

Effective for COVID-19 vaccines administered on or after March 15, 2021, the national average payment rate for physicians, hospitals, pharmacies, and many other immunizers will be \$40 to administer each dose of a COVID-19 vaccine. This represents an increase from approximately \$28 to \$40 for the administration of single-dose vaccines and an increase from approximately \$45 to \$80 for the administration of COVID-19 vaccines requiring two doses.

The exact payment rate for administration of each dose of a COVID-19 vaccine will depend on the type of entity that furnishes the service and will be geographically adjusted based on where the service is furnished.



Payment Allowances and Effective Dates for COVID-19 Vaccines and their Administration during the Public Health Emergency:

Code	CPT Short Descriptor	Labeler Name	Vaccine/Procedure Name	Payment Allowance	Effective Dates
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	Pfizer-Biontech Covid-19 Vaccine	\$0.010*	12/11/2020 – TBD
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – First Dose	\$16.940**	12/11/2020 – TBD
0002A	ADM SARSCOV2 30MCG/0.3ML 2ND	Pfizer	Pfizer-Biontech Covid-19 Vaccine Administration – Second Dose	\$28.390**	12/11/2020 – TBD
91301	SARSCOV2 VAC 100MCG/0.5ML IM	Moderna	Moderna Covid-19 Vaccine	\$0.010*	12/18/2020 – TBD
0011A	ADM SARSCOV2 100MCG/0.5ML1ST	Moderna	Moderna Covid-19 Vaccine Administration – First Dose	\$16.940**	12/18/2020 – TBD
0012A	ADM SARSCOV2 100MCG/0.5ML2ND	Moderna	Moderna Covid-19 Vaccine Administration – Second Dose	\$28.390**	12/18/2020 – TBD
91302	SARSCOV2 VAC 5X10 [^] 10VP/.5MLIM	AstraZeneca	AstraZeneca Covid-19 Vaccine	\$0.010*	xx/xx/xxxx – TBD
0021A	ADM SARSCOV2 5X10 [^] 10VP/.5ML 1	AstraZeneca	AstraZeneca Covid-19 Vaccine Administration – First Dose	\$16.940**	xx/xx/xxxx – TBD
0022A	ADM SARSCOV2 5X10 [^] 10VP/.5ML 2	AstraZeneca	AstraZeneca Covid-19 Vaccine Administration – Second Dose	\$28.390**	xx/xx/xxxx – TBD
91303	SARSCOV2 VAC AD26 .5ML IM	Janssen	Janssen Covid-19 Vaccine	\$0.010*	02/27/2021 – TBD
0031A	ADM SARSCOV2 VAC AD26 .5ML	Janssen	Janssen Covid-19 Vaccine Administration	\$28.390**	02/27/2021 – TBD

NDC - HCPCS Crosswalk for COVID-19

Effective from 11/09/2020 through the duration of Public Health Emergency

The ASP crosswalks are maintained by the Division of Ambulatory Services to support ASP-based Medicare Part B payments only. The crosswalks are intended to help the public (including entities that submit manufacturer ASP data and providers who bill for drugs) understand which drug products (identified by NDCs) are assigned to which HCPCS billing codes. The crosswalks are not intended to be a comprehensive list of all drugs/NDCs available in the United States. The NDC to HCPCS Crosswalk also includes information on the NDC package size and the number of billable units (as defined by the HCPCS code descriptor). Comments on the file may be sent to sec303aspdata@cms.hhs.gov.

HCPCS Code	Short Descriptor	LABELER NAME	NDC	DRUG NAME	HCPCS DOSAGE	PKG SIZE	PKG QTY	BILLUNIT S	BILLUNIT SPKG
Q0239	bamlanivimab-xxxx	Eli Lilly and Company	00002-7910-01	Bamlanivimab	700 MG	20	1	1	1
M0239	bamlanivimab-xxxx infusion	Eli Lilly and Company	N/A	Bamlanivimab Infusion	1 EA				
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	59267-1000-02	Pfizer-Biontech Covid-19 Vaccine	30 MCG	1	195	5	975
91300	SARSCOV2 VAC 30MCG/0.3ML IM	Pfizer	59267-1000-03	Pfizer-Biontech Covid-19 Vaccine	30 MCG	1	25	5	125
0001A	ADM SARSCOV2 30MCG/0.3ML 1ST	Pfizer	N/A	Pfizer-Biontech Covid-19 Vaccine Administration - First Dose	1 EA				
0002A	ADM SARSCOV2 30MCG/0.3ML 2ND	Pfizer	N/A	Pfizer-Biontech Covid-19 Vaccine Administration - Second Dose	1 EA				
91301	SARSCOV2 VAC 100MCG/0.5ML IM	Moderna	80777-0273-99	Moderna Covid-19 Vaccine	100 MCG	5	10	10	100
0011A	ADM SARSCOV2 100MCG/0.5ML1ST	Moderna	N/A	Moderna Covid-19 Vaccine Administration - First Dose	1 EA				
0012A	ADM SARSCOV2 100MCG/0.5ML2ND	Moderna	N/A	Moderna Covid-19 Vaccine Administration - Second Dose	1 EA				

Vaccine Code	Vaccine Code Descriptor	Vaccine Administration Code(s)	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	0001A (1 st dose) 0002A (2 nd dose)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1000-1 59267-1000-01	21 days
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	0011A (1 st dose) 0012A (2 nd dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	28 days
91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use	0021A (1 st Dose) 0022A (2 nd Dose)	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 Days



Updated Information for COVID-19

[Medicare Part A and Part B Billing for the COVID-19 Vaccine and Monoclonal Antibody - News and Alerts - Part B \(ngsmedicare.com\)](#)

[Medicare Billing for COVID-19 Vaccine Shot Administration | CMS](#)

You'll be able to bill on single claims for the COVID-19 vaccine administration or submit claims on a roster bill for multiple patients at one time.

When COVID-19 vaccine doses are provided by the government without charge, only bill for the vaccine administration. Do not include the vaccine codes on the claim when the vaccines are free.

If the Medicare beneficiary is enrolled in a Medicare Advantage Plan, submit your COVID-19 claims to original fee-for-service Medicare. This applies to all patients enrolled in Medicare Advantage in 2020 and 2021.



Updated Information for COVID-19

For billing single (non-roster) claims for COVID-19 vaccines and monoclonal antibodies, follow the instructions below.

Revenue Codes:

0771 – Preventive care services, vaccine administration

0636 – Pharmacy, requiring detailed coding

Note: Do not bill the drug/revenue code 0636 when the drug is provided free of charge

Monoclonal antibody infusions:

Medicare coverages all costs for monoclonal antibody infusion without any copayment due from the Medicare beneficiary; therefore, all costs for any saline (or other fluid) used for the infusion, as well as Benadryl (or any other drug), is bundled into the administration fee and should not be separately billed on the claim



Updated Information for COVID-19

For billing single claims for COVID-19 vaccines and monoclonal antibodies, follow the instructions below:

Patients name, address, Medicare number, date of birth and gender

Date of service

Beneficiary signature or stamped “Signature on File”

Providers name and identification number

Control number for contractor

Condition Codes:

A6 – 100% payment

78 - New coverage not implemented by Medicare Advantage (Billed on claims for Medicare Advantage beneficiaries only)

Diagnosis Codes:

COVID-19 vaccination:

Z23 - Encounter for immunization

Monoclonal antibody infusion:

Z23 - Encounter for immunization (Primary diagnosis)

U071 as appropriate (Secondary diagnosis)



Updated Information for COVID-19

Roster Billing:

Streamlined process for submitting vaccination claims for large groups of individuals.

If you use [roster billing](#) for institutional claims, you must administer shots to at least five patients on the same date, unless the institution is an inpatient hospital.

All patients have the same service date

Not used for single patient billing

The patient roster form includes the following with a single modified CMS-1500 claim form as roster cover document for each facility where the services are rendered:

For roster billing and centralized billing refer to the [Medicare Billing for COVID-19 Vaccine Shot Administration](#) web page.

Roster form for patients ([contact your MAC](#)) for this form)

Listing of MACs:

[COVID-19 MAC Webpages, Hotlines, and PC-ACE Software \(cms.gov\)](#)

